BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive

Last year, Pfizer and Bristol-Myers Squibb’s Eliquis replaced Johnson & Johnson’s Xarelto as the leader of the novel oral anticoagulant class. And now it’s about to unseat an even bigger foe: warfarin.